Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge.
|
31085175 |
2019 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
That ponatinib briefly induced remission in our patient with acute myeloid leukemia arising from a myeloproliferative neoplasm with eosinophilia and FIP1L1-PDGFRα fusion may merit exploration of ponatinib as a potential second-line treatment option for this patient population.
|
30184522 |
2018 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The purpose of this review is to provide an overview of the differential diagnosis for eosinophilia, to recommend specific steps for the pathologist evaluating blood and bone marrow, and to emphasize 2 important causes of eosinophilia that require specific ancillary tests for diagnosis: myeloproliferative neoplasm with PDGFRA rearrangement and lymphocyte-variant hypereosinophilic syndrome.
|
27684977 |
2016 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
|
26319757 |
2015 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Whereas FIP1L1-PDGFRα alone induced acute T-cell leukemia or myeloproliferative neoplasms in mouse bone marrow transplantation models, mice transplanted with bone marrow cells expressing both Hes1 and FIP1L1-PDGFRα developed acute leukemia characterized by an expansion of myeloid blasts and leukemic cells without eosinophilic granules.
|
24486648 |
2014 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In BCR-ABL1-negative myeloproliferative neoplasms (MPNs) several different tyrosine kinase fusion events have been described, most commonly involving the genes encoding the platelet-derived growth factor receptor alpha (PDGFRA) or beta (PDGFRB).
|
23186533 |
2013 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
However, after treatment with hydroxyurea and serial phlebotomies had been started, the patient developed hypereosinophilia, fitting the category of a myeloproliferative neoplasm with eosinophilia associated with the FIP1L1-PDGFRA gene fusion, as confirmed by molecular analysis.
|
22944561 |
2012 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.
|
22722648 |
2012 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The introduction of JAK2 mutation testing has changed dramatically the diagnostic algorithms for myeloproliferative neoplasms (MPNs) but there is still a place for conventional cytogenetic analysis in the initial work-up of MPN cases, particularly as this group of myeloid disorders has been expanded to include chronic eosinophilic leukaemia and myeloid neoplasms with abnormalities of the PDGFRA, PDGFRB, and FGFR1 genes.
|
21431636 |
2011 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations.
|
20191332 |
2010 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
This review highlights the important diagnostic tools in classical and atypical myeloproliferative neoplasms mainly the JAK2V617F mutation, the Mpl receptor, Polycythemia rubra vera 1 (PRV1), platelet-derived growth-factor receptor alpha (PDGFRA), platelet-derived growth-factor receptor beta (PDGFRB), fibroblast growth-factor receptor 1 (FGFR1) and c-kit tyrosine kinase.
|
20126996 |
2010 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Rapid identification of diverse fusion genes with involvement of PDGFRA or PDGFRB in eosinophilia-associated myeloproliferative neoplasms is essential for adequate clinical management but is complicated by the multitude and heterogeneity of partner genes and breakpoints.
|
20107158 |
2010 |
Myeloproliferative disease
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Imatinib is usually a highly effective treatment for myeloproliferative neoplasms (MPNs) associated with ABL, PDGFRA or PDGFRB gene fusions; however, occasional imatinib-responsive patients have been reported without abnormalities of these genes.
|
18971950 |
2009 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The FIP1L1-PDGFRA fusion gene is a recurrent molecular abnormality in patients with eosinophilia-associated myeloproliferative neoplasms.
|
18987651 |
2009 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions.
|
19147089 |
2009 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
LHGDN |
Platelet-derived growth factor may be associated with fibrosis in a Down syndrome patient with transient myeloproliferative disorder.
|
18331602 |
2008 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
We investigated genetically affected leukemic cells in FIP1L1-PDGFRA+ chronic eosinophilic leukemia (CEL) and in BCR-ABL1+ chronic myeloid leukemia (CML), two myeloproliferative disorders responsive to imatinib.
|
17215855 |
2007 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
BEFREE |
The FIP1L1-PDGFRA fusion gene is a recurrent molecular lesion in eosinophilia-associated myeloproliferative disorders, predicting a favorable response to imatinib mesylate.
|
17299092 |
2007 |
Myeloproliferative disease
|
0.200 |
AlteredExpression
|
group |
LHGDN |
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
|
16498388 |
2006 |
Myeloproliferative disease
|
0.200 |
PosttranslationalModification
|
group |
BEFREE |
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
|
12781364 |
2003 |
Myeloproliferative disease
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|